Moleculin Biotech (MBRX) Leases (2018 - 2025)
Moleculin Biotech (MBRX) has 8 years of Leases data on record, last reported at $343000.0 in Q3 2025.
- For Q3 2025, Leases fell 23.78% year-over-year to $343000.0; the TTM value through Sep 2025 reached $343000.0, down 23.78%, while the annual FY2024 figure was $424000.0, 19.08% down from the prior year.
- Leases reached $343000.0 in Q3 2025 per MBRX's latest filing, down from $370000.0 in the prior quarter.
- Across five years, Leases topped out at $547000.0 in Q3 2023 and bottomed at $81000.0 in Q1 2022.
- Average Leases over 5 years is $352473.7, with a median of $398000.0 recorded in 2025.
- Peak YoY movement for Leases: plummeted 54.75% in 2022, then surged 370.37% in 2023.
- A 5-year view of Leases shows it stood at $107000.0 in 2021, then surged by 276.64% to $403000.0 in 2022, then skyrocketed by 30.02% to $524000.0 in 2023, then dropped by 19.08% to $424000.0 in 2024, then dropped by 19.1% to $343000.0 in 2025.
- Per Business Quant database, its latest 3 readings for Leases were $343000.0 in Q3 2025, $370000.0 in Q2 2025, and $398000.0 in Q1 2025.